Imfinzi plus Imjudo approved in EU for advanced cancers : vi

Hepatocellular carcinoma and lung cancer patients are set to benefit from the recent approval of Imfinzi plus Imjudo combinations in the EU.

Related Keywords

Switzerland , Astrazeneca Imfinzi , Bruno Sangro , Hospitalier Universitaire Vaudois , Solange Peters , Tremelimumab Astrazeneca , Head Of The Medical Oncology Service , European Union , European Commission , Committee For Medicinal Products Human Use , Medicinal Products , Human Use , New England Journal , Medical Oncology Service , Thoracic Oncology , Liver Unit , Internal Medicine , Universidad De Navarra ,